Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of hybutimibe + atorvastatin versus atorvastatin in adults with hypercholesterolemia inadequately controlled on statin monotherapy
CTR20262200Phase 3Active
- Sponsor
- Hanhui Pharmaceutical
- Start
- Jun 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hybutimibe, atorvastatin in hypercholesterolemia, combined dyslipidaemia, sponsored by Hanhui Pharmaceutical. Started Jun 2026; status: active.
02
Drugs
hybutimibeatorvastatin
03
Conditions
hypercholesterolemiacombined dyslipidaemia
Beyond the preview
Go deeper on CTR20262200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262200.